» Articles » PMID: 6088019

Primary Liver Cancer. An Eastern Cooperative Oncology Group Trial

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 1984 Sep 15
PMID 6088019
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

One hundred ninety-two patients with unresectable primary liver cancer studied by members of the Eastern Cooperative Oncology Group (ECOG) were evaluable in a prospectively randomized clinical trial. Patient discriminants such as performance status were carefully evaluated to assess their influence on prognosis and to evaluate the importance of patient status on response and survival. Patients who were totally bedridden or with signs of overt liver failure were not entered on study. The median survival time for all evaluable previously untreated patients was 17 weeks (19 weeks for North American and European, and 10 weeks for South African black patients). Among the South African patients, however, there was a significantly larger proportion with an initially poor performance status. Prognostic variables (performance status, jaundice, and reduced appetite) dominate any differences among the treatments studied. Among North American and European patients on intravenous (IV) 5-fluorouracil (5-FU) + Methyl-CCNU (MeCCNU) + Adriamycin (ADM, doxorubicin), the 19% response rate is offset by 63% with severe toxicity and a median survival time of only 17 weeks, making this treatment unacceptable clinically. The median survival time of North American and European patients treated with IV 5-FU +/- MeCCNU was 28 weeks in contrast to a median survival time of 12 weeks with ADM (P less than or equal to 0.01). EST 2273 was the ECOG study of patients with primary liver cancer. The results of the first part of the trial were published in 1978. This report updates those findings and reports the results of patients entered subsequently on the second part of that study after it was amended in 1979. With more than 300 evaluable patients in EST 2273, this duet of studies is the largest ever conducted in patients with primary liver cancer, and draws a new baseline from which to measure the disease and its response to treatment.

Citing Articles

TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.

Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L Eur Radiol. 2018; 29(3):1285-1292.

PMID: 30171360 DOI: 10.1007/s00330-018-5692-8.


A case of hepatocellular carcinoma with pulmonary metastases treated successfully with a combination of repeated hepatic arterial infusion epirubicin and Cisplatin chemotherapy and systemic low-dose infusion of 5-Fluorouracil.

Oh Y, Park Y, Kim B, Kim M, Cho J, Cha C Gut Liver. 2010; 3(4):343-8.

PMID: 20431774 PMC: 2852739. DOI: 10.5009/gnl.2009.3.4.343.


Current management of advanced hepatocellular carcinoma.

Abou-Alfa G, Huitzil-Melendez F, OReilly E, Saltz L Gastrointest Cancer Res. 2009; 2(2):64-70.

PMID: 19259298 PMC: 2630820.


A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

Knox J, Chen X, Feld R, Nematollahi M, Cheiken R, Pond G Invest New Drugs. 2007; 26(2):193-4.

PMID: 18060598 DOI: 10.1007/s10637-007-9104-1.


A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma.

Lo C, Liu C, Chan S, Ming Lam C, Poon R, Ng I Ann Surg. 2007; 245(6):831-42.

PMID: 17522506 PMC: 1876947. DOI: 10.1097/01.sla.0000245829.00977.45.